Who Should Wait for Retatrutide vs Starting Semaglutide Now?

Every week, patients ask their doctors the same question: "Should I hold off on starting semaglutide and wait for retatrutide?" It is a reasonable question. Retatrutide, Eli Lilly's triple-agonist drug targeting GLP-1, GIP, and glucagon receptors simultaneously, produced an average 24.2% body weight loss in Phase 2 trials -- results that approach bariatric surgery. Why settle for 15% weight loss with semaglutide when something potentially better is on the horizon?

The answer, for the vast majority of patients, is that waiting is a mistake. Obesity is not a cosmetic concern that can be put on hold. It is a progressive, chronic disease that causes compounding damage to your cardiovascular system, joints, liver, and metabolic health every month it goes untreated. The health benefits of starting treatment today almost always outweigh the theoretical advantages of waiting for a drug that is still years away from widespread availability.

But "almost always" is not "always." There are specific situations where a thoughtful wait-and-see approach might make sense. Let us break down the decision framework so you can make the best choice for your situation.

The Real Cost of Waiting

Before diving into who should or should not wait, it is critical to understand what "waiting" actually means in medical terms. Obesity is not a static condition. Every month of untreated obesity contributes to:

• Progressive cardiovascular damage: Elevated blood pressure, arterial inflammation, and lipid abnormalities cause cumulative harm. The SELECT trial demonstrated that semaglutide reduced major cardiovascular events by 20% -- benefits that compound over time.
• Worsening insulin resistance: The longer insulin resistance goes unaddressed, the more likely it is to progress to type 2 diabetes. Once diabetes develops, treatment becomes more complex and expensive.
• Joint degeneration: Excess weight accelerates osteoarthritis, particularly in knees and hips. Joint damage is largely irreversible -- weight loss can reduce pain and slow progression, but cannot undo cartilage loss.
• Fatty liver progression: Non-alcoholic fatty liver disease can progress to MASH (metabolic dysfunction-associated steatohepatitis), fibrosis, and eventually cirrhosis. Early weight loss can reverse fatty liver before permanent scarring occurs.
• Sleep apnea and metabolic disruption: Untreated sleep apnea from obesity further worsens cardiovascular risk, insulin resistance, and quality of life.
• Mental health burden: The psychological toll of living with untreated obesity -- including depression, anxiety, and reduced quality of life -- accumulates and can become harder to address over time.

A reasonable estimate of the retatrutide timeline: Phase 3 trials are expected to read out in late 2026, followed by FDA review that could take 6-12 months, followed by manufacturing scale-up and insurance coverage negotiations. Realistically, widespread access to retatrutide is unlikely before mid-to-late 2027 at the earliest. That is 18 or more months of continued untreated obesity for someone who decides to wait.

Who Should Start Treatment Now (The Majority)

For these patients, the calculation is straightforward. Starting semaglutide or tirzepatide today provides immediate, measurable health benefits. Even if retatrutide eventually proves superior, 18 months of effective treatment with current medications delivers far more benefit than 18 months of waiting. And you can always discuss transitioning to retatrutide with your provider once it becomes available.

The "Good Enough" Principle

Semaglutide produces average weight loss of 15-17%, and tirzepatide produces 20-22%. These are not consolation prizes -- they represent transformative, clinically meaningful weight loss that dramatically improves health outcomes. The difference between 17% and 24% weight loss, while statistically significant, is less important than the difference between 0% (waiting) and 17% (starting now).

Consider a 250-pound patient. Starting semaglutide now and losing 17% of body weight means dropping to approximately 207 pounds over 12-15 months. That 43-pound loss reduces blood pressure, improves insulin sensitivity, decreases liver fat, reduces joint stress, and lowers cardiovascular risk. Waiting 18 months for a shot at losing 24% instead means staying at 250 pounds -- and accumulating additional health damage -- during the entire waiting period.

Who Might Reasonably Consider Waiting

Even in these scenarios, "waiting" does not mean doing nothing. Patients who cannot or choose not to start pharmacotherapy should actively pursue lifestyle modification, metabolic monitoring, and regular check-ins with their healthcare provider.

The Start-Now-and-Switch Strategy

The most pragmatic approach for most patients combines the best of both worlds: start effective treatment now and plan a potential transition later. Here is how this strategy works in practice:

1. Start semaglutide or tirzepatide today. Begin capturing health benefits immediately. Learn how these medications work and what to expect.
2. Optimize your current treatment. Work with your provider to find the right dose, manage side effects, and integrate lifestyle changes for maximum benefit.
3. Monitor retatrutide developments. Follow the TRIUMPH trial results and FDA review timeline.
4. Evaluate switching when retatrutide becomes available. By then, you will have a track record with GLP-1 therapy that helps inform whether the incremental benefit of switching justifies the transition.
5. Some patients may not need to switch at all. If you achieve your health goals with semaglutide or tirzepatide, there may be no reason to change medications.

This approach eliminates the false binary of "semaglutide now OR retatrutide later." You get the benefits of both: immediate treatment with current medications and the option to upgrade when better options become available.

Current Advantages of Semaglutide and Tirzepatide

It is worth remembering that current FDA-approved medications have advantages that retatrutide cannot yet claim:

• Extensive real-world safety data: Semaglutide has been used by millions of patients, providing a robust understanding of its safety profile across diverse populations. Retatrutide has been tested in hundreds.
• Proven cardiovascular outcomes: The SELECT trial demonstrated semaglutide's cardiovascular benefits in a rigorous outcomes study. Retatrutide's TRIUMPH-3 cardiovascular outcomes trial is still underway.
• Established dosing protocols: Clinicians have years of experience optimizing semaglutide and tirzepatide dosing, managing side effects, and supporting patients through treatment.
• Insurance coverage: While still imperfect, insurance pathways for semaglutide and tirzepatide are established. New drugs often face initial coverage barriers.
• Compounded options: Affordable compounded formulations of semaglutide and tirzepatide are currently available, dramatically reducing cost barriers. Compounded retatrutide would not be available until well after brand approval, if at all.
• Long-term maintenance data: We know how semaglutide performs over 2+ years of treatment, including what happens during dose reduction and discontinuation. This data does not exist for retatrutide.

Common Reasoning Mistakes When Deciding to Wait

Several cognitive biases can lead patients to make suboptimal decisions about treatment timing:

The "Perfect Solution" Fallacy

Waiting for the theoretically best option while refusing a very good option available now. In medicine, this pattern is well-documented and consistently leads to worse outcomes. The best treatment is the one you actually start.

Underestimating Timeline Uncertainty

Patients often hear "retatrutide could be approved by 2027" and plan around the optimistic end. Drug development is unpredictable. The COVID-19 pandemic delayed many drug programs. Manufacturing issues, unexpected safety signals, or regulatory requests for additional data could push approval to 2028 or beyond.

Overweighting Marginal Improvements

The difference between 17% and 24% average weight loss sounds large, but individual variation within each medication is enormous. Some patients lose 25%+ on semaglutide, while some lose only 12% on retatrutide. You will not know which medication works best for you until you try.

Ignoring the Compounding Benefits of Early Treatment

Health benefits from weight loss compound over time. Starting 18 months earlier means 18 months of improved blood sugar, reduced cardiovascular strain, less joint damage, and better quality of life. These benefits do not just pause while you wait -- they are lost entirely.

A Practical Decision Framework

Use this structured approach to think through your decision:

The Bottom Line

Retatrutide is genuinely exciting. The Phase 2 data is remarkable, and if Phase 3 confirms these results, it will represent a meaningful advance in obesity treatment. But excitement about a future drug should not prevent you from accessing effective treatment available right now.

For the vast majority of patients with obesity, the answer is clear: start semaglutide or tirzepatide today and keep retatrutide on your radar for the future. You can always transition later. You cannot get back the health you lost while waiting.

Ready to explore your options? Visit our treatments page to compare currently available medications, or learn how the treatment process works at Trimi.